{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["11(24)"],"submitter":["Makita S"],"funding":["Celgene","Bristol-Myers Squibb"],"pubmed_abstract":["The autologous anti-CD19 chimeric antigen receptor (CAR) T-cell product, lisocabtagene maraleucel (liso-cel), is administered at equal target doses of CD8<sup>+</sup> and CD4<sup>+</sup> CAR<sup>+</sup> T cells. This analysis assessed safety and efficacy of liso-cel in Japanese patients with relapsed or refractory (R/R) aggressive large B-cell lymphoma (LBCL) in Cohort 3 of TRANSCEND WORLD (NCT03484702). Liso-cel (100 × 10<sup>6</sup> total CAR<sup>+</sup> T cells) was administered 2-7 days after lymphodepletion. The primary efficacy endpoint was objective response rate (ORR; Lugano 2014 criteria) assessed by an independent review committee. Fourteen patients were enrolled; 10 received liso-cel infusion (median time to liso-cel availability, 23 days) and were evaluable at data cutoff (medi"],"journal":["Cancer medicine"],"pagination":["4889-4899"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9761090"],"repository":["biostudies-literature"],"pubmed_title":["Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma."],"pmcid":["PMC9761090"],"pubmed_authors":["Stepan L","Rettby N","Izutsu K","Ananthakrishnan R","Yamamoto G","Ogasawara K","Makita S","Asano-Mori Y","Kaji D","Schusterbauer C","Maruyama D","Hasskarl J"],"additional_accession":[]},"is_claimable":false,"name":"Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.","description":"The autologous anti-CD19 chimeric antigen receptor (CAR) T-cell product, lisocabtagene maraleucel (liso-cel), is administered at equal target doses of CD8<sup>+</sup> and CD4<sup>+</sup> CAR<sup>+</sup> T cells. This analysis assessed safety and efficacy of liso-cel in Japanese patients with relapsed or refractory (R/R) aggressive large B-cell lymphoma (LBCL) in Cohort 3 of TRANSCEND WORLD (NCT03484702). Liso-cel (100 × 10<sup>6</sup> total CAR<sup>+</sup> T cells) was administered 2-7 days after lymphodepletion. The primary efficacy endpoint was objective response rate (ORR; Lugano 2014 criteria) assessed by an independent review committee. Fourteen patients were enrolled; 10 received liso-cel infusion (median time to liso-cel availability, 23 days) and were evaluable at data cutoff (medi","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Dec","modification":"2025-04-26T00:48:11.77Z","creation":"2025-04-06T09:49:36.368Z"},"accession":"S-EPMC9761090","cross_references":{"pubmed":["35619325"],"doi":["10.1002/cam4.4820"]}}